Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial.
Chaoying Gu, Aijun Chen, Huibin Yin et al.
✦ AI-curated · Sources linked
In 30 seconds
This post-hoc subgroup analysis examined efficacy and safety of ivarmacitinib in patients with moderate to severe atopic dermatitis, using data from a randomized, double-blind, placebo-controlled, multicenter phase 3 trial. Participants had been assigned to ivarmacitinib 4 mg, 8 mg, or placebo for 16 weeks. At week 16, both doses showed better responses than placebo for EASI 75, EASI 90, and a ≥4-point improvement in WI-NRS in most subgroups defined by baseline characteristics. Overall adverse-event incidence and most adverse events of special interest were similar across treatment groups.
Key findings
- At week 16, both ivarmacitinib doses outperformed placebo for EASI 75 and EASI 90 responses in most baseline-characteristic subgroups.
- Both doses also showed better placebo-comparative rates of ≥4-point WI-NRS improvement in most subgroups.
- Overall adverse-event incidence and most adverse events of special interest were similar between ivarmacitinib and placebo across subgroups.
Why it matters
The subgroup results suggest that efficacy and tolerability observed with ivarmacitinib were not confined to a narrow set of baseline patient characteristics. This may help inform interpretation of trial findings across varied clinical profiles, while the post-hoc nature of the analysis and absence of subgroup-specific effect estimates in the abstract limit conclusions about differences between groups.
What to keep in mind
This was a post-hoc subgroup analysis of a 16-week trial; the abstract does not provide subgroup-specific effect estimates.